Q2 FY2026 · ended Jun 30, 2026 · Revenue $5,000, -99.7% YoY · Filed Aug 11, 2026
Bolt Biotherapeutics, Inc. (BOLT) files with the SEC under industry code 2834, Pharmaceutical Preparations. In Q2 of fiscal 2026, the quarter ended Jun 30, 2026, it reported revenue of $5,000 and a net loss of $7.7 million. Free cash flow was -$6.6 million. As of Jun 30, 2026 it held $18.1 million in cash and investments and $21.6 million in total debt.
Revenue
$5,000
-99.7% vs year-ago quarter
Net income
$-7.72M
+9.8% vs year-ago quarter
Operating cash flow
$-6.54M
+31.9% vs year-ago quarter
Free cash flow
$-6.55M
+8.4% vs prior quarter
EPS
$-4.57
-2.5% vs year-ago quarter
Dividend per share
None
Shares outstanding
1.93M
+0.4% vs year-ago quarter
Net cash
$-3.52M
Q2 FY2026
Operating margin
-654.5%
TTM
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- BOLT (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Redwood City, CA
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1641281
- Former names
- Bolt Therapeutics, Inc. (until May 7, 2015)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q2 FY2026 Jun 30, 2026 |
Q1 FY2026 Mar 31, 2026 |
Q4 FY2025 Dec 31, 2025 |
Q3 FY2025 Sep 30, 2025 |
Q2 FY2025 Jun 30, 2025 |
|---|---|---|---|---|---|
| Revenue | $5,000 | $26,000 | $2.5M | $2.2M | $1.8M |
| Operating income | -$8.4M | -$7.6M | -$7.1M | -$7.7M | -$9.2M |
| Net income | -$7.7M | -$7.2M | -$6.6M | -$7.1M | -$8.6M |
| Diluted EPS | -$4.57 | -$4.31 | -$3.84 | -$3.72 | -$4.46 |
| Operating cash flow | -$6.5M | -$8.0M | -$7.2M | -$9.7M | -$9.6M |
| Free cash flow | -$6.6M | — | -$7.2M | -$9.8M | — |
| Total assets | $40.3M | $48.0M | $56.7M | $65.1M | $75.5M |
| Total liabilities | $27.7M | $28.2M | $30.2M | $33.0M | $36.7M |
| Stockholders' equity | $12.6M | $19.8M | $26.5M | $32.1M | $38.8M |
| Cash and investments | $18.1M | $23.9M | $31.8M | $38.8M | $48.5M |
| Total debt | $21.6M | $22.3M | $23.0M | $23.6M | $24.2M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Material agreement, Agreement ended, Acquisition or sale of assets, Unregistered share sale, Officer or director change, Bylaw or fiscal year change, Regulation FD disclosure, Other events
|
Oct 23, 2026 | Oct 23, 2026 |
| 8-K |
Current report
Material agreement
|
Oct 6, 2026 | Oct 1, 2026 |
| 10-Q | Quarterly report | Aug 11, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 11, 2026 | Aug 11, 2026 |
| 8-K |
Current report
Shareholder vote results
|
Jun 11, 2026 | Jun 11, 2026 |
| 10-Q | Quarterly report | May 12, 2026 | Mar 31, 2026 |
All 294 Bolt Biotherapeutics, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.